Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings results on Monday. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03), FiscalAI reports.

Acurx Pharmaceuticals Stock Performance

Acurx Pharmaceuticals stock traded up $0.09 during trading hours on Monday, reaching $2.18. 105,986 shares of the stock were exchanged, compared to its average volume of 2,198,141. Acurx Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $21.00. The stock has a market cap of $6.23 million, a P/E ratio of -0.39 and a beta of -2.09. The firm’s 50 day moving average is $3.04 and its 200 day moving average is $3.37.

Analysts Set New Price Targets

A number of research analysts have recently commented on ACXP shares. Wall Street Zen upgraded Acurx Pharmaceuticals to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the second quarter valued at about $551,000. Millennium Management LLC purchased a new position in shares of Acurx Pharmaceuticals during the 4th quarter worth approximately $103,000. Geode Capital Management LLC acquired a new stake in shares of Acurx Pharmaceuticals in the 4th quarter valued at approximately $31,000. Finally, Jane Street Group LLC acquired a new stake in shares of Acurx Pharmaceuticals in the 4th quarter valued at approximately $27,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).